RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Employees

Sector

Biotechnology & Medical Research

Calendar

Nov. 11 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
26-10-30	¥64.00	-3.03%	162,500
26-10-29	¥66.00	+1.54%	224,800
26-10-28	¥65.00	+1.56%	200,300
26-10-27	¥64.00	-1.54%	209,400
26-10-26	¥65.00	-1.52%	270,000

Delayed Quote Japan Exchange

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Ribomic Inc.

Company calendar

Market Closed - Japan Exchange 02:30:00 2026-10-30 am EDT			5-day change	1st Jan Change
64.00 ^JPY	-3.03%		-1.54%	-17.95%

Oct. 20	RIBOMIC, Inc. Enters Into Technology Evaluation Agreement For DDS Aptamer Asset With A Biotechnology Company Based Outside Japan	CI
Oct. 06	RIBOMIC, Inc. Announces Interim Report On Phase 2 Long-Term Clinical Trial Of Umedaptanib Pegol In Treatment Of Achondroplasia	CI

Market Cap	3.64B 23.08M 20.67M 19.02M 17.23M 32.21M 2.19B 32.81M 227M 91.03M 1.15B 86.63M 84.78M	P/E 2025	-3.89x	P/E 2026	-3.82x
Enterprise Value	809M 5.13M 4.6M 4.23M 3.83M 7.16M 488M 7.3M 50.44M 20.25M 256M 19.27M 18.86M	EV / Sales 2025	666x	EV / Sales 2026	651x
Free-Float	97.07%	Yield 2025 *	-	Yield 2026	-

Oct. 20	RIBOMIC, Inc. Enters Into Technology Evaluation Agreement For DDS Aptamer Asset With A Biotechnology Company Based Outside Japan	CI
Oct. 06	RIBOMIC, Inc. Announces Interim Report On Phase 2 Long-Term Clinical Trial Of Umedaptanib Pegol In Treatment Of Achondroplasia	CI
Sep. 29	RIBOMIC, Inc. Announces No Safety Concerns After Three Months Of 1 Mg/Kg Weekly Treatment With Umedaptanib Pegol In Achondroplasia Phase 2 Study	CI
Aug. 24	Ribomic Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia	CI
Aug. 13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
Aug. 13	Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
Jul. 02	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
Jul. 01	Ribomic Inc. Announces First Patient Enrollment In Phase 3 Clinical Trial Of Umedaptanib Pegol For Achondroplasia	CI
May. 14	Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
Mar. 19	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
Mar. 19	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI
Mar. 10	Ribomic Reports Positive Phase II Results For Achondroplasia Drug	MT
Mar. 10	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia	CI

25-10-07	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
24-11-05	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
24-08-03	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
23-12-05	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
22-07-29	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU

Ribomic Inc. Stock

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Valuation: Ribomic Inc.

Chart: Ribomic Inc.

Latest news: Ribomic Inc.

Press Releases: Ribomic Inc.

News in other languages: Ribomic Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Ribomic Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

25-10-08	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
24-11-06	RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachstumsrate von bis zu +4,6 cm/Jahr bei Kindern ab 5 Jahren in der niedrig dosierten...
20-02-20	RIBOMIC : kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
19-06-19	RIBOMIC : gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt

1 day	-3.03%
1 week	-1.54%
Current month	-20.00%
1 month	-17.95%
3 months	-9.86%
6 months	-18.99%
Current year	-17.95%

Manager	Title	Age	Since
Yoshikazu Nakamura PSD	President	78	2012-03-31
Toshiya Imai DFI	Director of Finance/CFO	-	-
Takeo Adachi CTO	Chief Tech/Sci/R&D Officer	39	2023-09-30

Director	Title	Age	Since
Yoshikazu Nakamura BRD	Director/Board Member	78	2005-09-30
Toshiaki Nishihata BRD	Director/Board Member	77	2016-05-31
Takeo Adachi BRD	Director/Board Member	39	2024-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RIBOMIC INC.	-3.03%	-1.54%	-28.09%	-49.21%	23.75M
WUXI APPTEC CO., LTD.	-0.62%	+0.50%	+33.92%	+60.07%	64.38B
ARGENX SE	+0.35%	+3.20%	+14.92%	+84.55%	56.16B
LONZA GROUP AG	+0.53%	+1.96%	+15.37%	+106.81%	54.16B
IQVIA HOLDINGS INC.	-3.88%	-5.00%	+22.59%	+49.80%	45.33B
BEONE MEDICINES AG	-0.32%	-1.60%	+20.56%	+99.13%	42.25B
REVOLUTION MEDICINES, INC.	-0.39%	+1.06%	+221.01%	+929.86%	40.78B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	33.8B
CELLTRION, INC.	+1.22%	-1.39%	+13.92%	+46.95%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.29%	-1.72%	+21.00%	-6.85%	23.57B
Average	-0.43%	+4.40%	+44.79%	+141.76%	39.27B
Weighted average by Cap.	-0.22%	+3.64%	+49.69%	+161.39%

	2025	2026
Net sales	2M 12.7K 11.37K 10.46K 9.48K 17.72K 1.21M 18.05K 125K 50.07K 634K 47.65K 46.64K	3M 19.05K 17.06K 15.69K 14.22K 26.57K 1.81M 27.07K 187K 75.11K 951K 71.48K 69.96K
Net income	-1.02B -6.46M -5.79M -5.32M -4.82M -9.02M -614M -9.19M -63.49M -25.49M -323M -24.25M -23.74M	-1.14B -7.27M -6.51M -5.99M -5.43M -10.14M -690M -10.33M -71.41M -28.67M -363M -27.28M -26.7M
Net Debt	-3.04B -19.28M -17.27M -15.88M -14.39M -26.9M -1.83B -27.41M -189M -76.04M -963M -72.36M -70.82M	-2.83B -17.95M -16.07M -14.79M -13.4M -25.04M -1.7B -25.51M -176M -70.78M -896M -67.36M -65.92M

1 week	64	67
1 month	62	80
Current year	57	120
1 year	57	120
3 years	57	141
5 years	57	944
10 years	57	1,109